GIPR in GH-PitNETs: molecular and functional insights
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-25-0106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Mattia Dalle Nogare und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Padova, Padova, Italy. Hauptthemen laut MEDLINE: Receptors, Gastrointestinal Hormone, Growth Hormone-Secreting Pituitary Adenoma, Neuroendocrine Tumors, Pituitary Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Acromegaly, primarily caused by GH-secreting pituitary neuroendocrine tumors (GH-PitNETs), in about half of cases exhibits resistance to somatostatin receptor ligands (SRLs), making surgery the primary treatment. Recent evidence suggests that glucose-dependent insulinotropic polypeptide receptor (GIPR) overexpression in a subset of GH-PitNETs contributes to disease heterogeneity, particularly in tumors showing a paradoxical GH rise after glucose load, which are associated with a less aggressive phenotype and better first-generation SRLs response. This study investigated the functional role of GIPR in somatotroph cells by generating stable human GIPR-expressing GH3 cells (GH3 hGIPR ) and comparing them with empty vector controls. Functional assays demonstrated that GIPR activation induces cAMP/PKA and MAPK/ERK signaling, enhances GH and prolactin secretion, and increases intracellular calcium oscillations, dependent on extracellular calcium influx. Transcriptomic analysis revealed differential gene expression patterns linked to cell motility, neuronal development, and extracellular matrix remodeling in GH3 hGIPR cells, aligning with clinical observations in GIPR + tumors. However, GIPR overexpression did not alter cell proliferation or viability, suggesting that its role in tumor behavior may depend on additional molecular or epigenetic factors. These findings highlight the importance of GIPR signaling in somatotroph cell function and its potential influence on therapeutic responses, though further studies are needed to clarify its contribution to tumorigenesis and SRL sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, University of Padova, Padova, Italy.
- Department of Medicine, University of Padova, Padova, Italy.
- Department of Biomedical Sciences, University of Padova, Padova, Italy.
- Italian National Research Council (CNR), Neuroscience Institute, Padova, Italy.
- Department of Molecular Medicine, University of Pavia, Pavia, Italy.
- Foundation for Advanced Biomedical Research, Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.
ORCID-Profile: Mattia Dalle Nogare, Serena Avallone, Luna Picello, Daniele Puggina, Gianluca Occhi
Zitieren
APA
Dalle Nogare, M., Avallone, S., Galletta, E., Perbellini, G., Pallafacchina, G., Picello, L., Puggina, D., Vismara, M., Sales, G., Vazza, G., Regazzo, D., & Occhi, G. (2025). GIPR in GH-PitNETs: molecular and functional insights. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0106
Vancouver
Dalle Nogare M, Avallone S, Galletta E, Perbellini G, Pallafacchina G, Picello L, et al. GIPR in GH-PitNETs: molecular and functional insights. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0106
BibTeX
@article{DalleNogare2025,
author = {Dalle Nogare, Mattia and Avallone, Serena and Galletta, Eva and Perbellini, Giorgia and Pallafacchina, Giorgia and Picello, Luna and Puggina, Daniele and Vismara, Mauro and Sales, Gabriele and Vazza, Giovanni and Regazzo, Daniela and Occhi, Gianluca},
title = {GIPR in GH-PitNETs: molecular and functional insights},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-25-0106}
}
EUVIMED